DESTINY-Breast05
Enhertu cut recurrence or death by more than half compared with Kadcyla in women with cancer left after pre-surgery treatment, replacing the KATHERINE standard.
Interim analysis (ESMO 2025, LBA1): 3-year iDFS 92.4% vs 83.7%, HR 0.47 (P<0.0001). More ILD with T-DXd. FDA approved the post-neoadjuvant indication in Q2 2026 alongside the neoadjuvant DESTINY-Breast11 indication.
- 92.4 vs 83.7 out of 100 alive without the cancer coming back at 3 years with T-DXd compared with T-DM1; 8.7 more per 100.
- Roughly one extra person helped for every 11 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- Put another way, the treated group had about 53 percent lower chance of the event at any given time (hazard ratio 0.47, likely range 0.34 to 0.66).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- These results apply to the people the trial enrolled: High-risk HER2+ early breast cancer with residual invasive disease after neoadjuvant therapy: T-DXd vs T-DM1. People in a different situation may not see the same effect.
- The trial selected people by a biomarker (HER2); the result should not be assumed for people whose cancer does not have it.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
1,635 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| 3-year invasive disease-free survivalprimary | T-DXd | — | 92.4% | 0.47 (0.34–0.66) | <0.0001 | link |
| T-DM1 | — | 83.7% |
Pages like this
not linked directly; found by shared links- TrialDESTINY-Breast11
Shares Can T-DXd alone cure early HER2-positive disease?, Trastuzumab deruxtecan, HER2-positive breast cancer.
- TrialHER2CLIMB-02
- PersonSung-Bae Kim
Shares Trastuzumab emtansine, Trastuzumab deruxtecan, HER2-positive breast cancer.
- IdeaSequencing HER2 ADCs by payload after T-DXd
Shares Trastuzumab emtansine, Trastuzumab deruxtecan, HER2-positive breast cancer.
- ProductTrastuzumab duocarmazine
- PersonGunter von Minckwitz
- TrialDESTINY-Breast03
Shares Trastuzumab emtansine, Trastuzumab deruxtecan, HER2-positive breast cancer.
- PersonSara A. Hurvitz
Shares Trastuzumab emtansine, Trastuzumab deruxtecan, HER2-positive breast cancer.